eaking Kim Giordano, MSN, CRNP. CORLN Fall SOHN 2015 The following will be a discussion about the emerging use of Biologic medications.
|
|
- Evangeline Curtis
- 6 years ago
- Views:
Transcription
1 eaking Kim Hoffmann Giordano, MSN, CRNP, CORLN Division of Otolaryngology The Children s Hospital of Philadelphia The following will be a discussion about the emerging use of Biologic medications. Highlighting on the basics of the Biological Revolution & how these complex compounds that are changing the quality of lives for patients with autoimmune diseases. Definition of Health: A state of complete physical, mental and social well being and not merely the absence of disease or infirmity World Health Organization Definition of Chronic Illness: Any disorder that persists over a long period and affects physical, emotional, intellectual, vocational, social, or spiritual functioning Wikipedia Definition of Quality of Life: The standard of health, comfort, and happiness experienced by an individual or group Wikipedia 1
2 The last decade has seen a revolution in the treatment of patients of chronic immuno inflammatory diseases These include disease processes such as: Rheumatoid Arthritis Psoriasis Plaque Psoriasis Psoriatic Arthritis Inflammatory Bowel Diseases Crohn s Disease Ulcerative Colitis Approximately 20 years ago, it started with an appreciation of the possible role of TNF α in the pathogenesis of auto immune disease This lead to an understanding that provided the basis for the development and use of genetically engineered biopharmaceuticals specifically targeting TNF α in patients with chronic inflammatory disorders Bendtzen, K. Immunotherapy:
3 Anti TNF inhibitor is a pharmaceutical drug that suppresses response to Tumor Necrosis Factor (TNF), which is part of the inflammatory response TNF is a cytokine of the immune system characterized by modulating cell death, proliferation, and inflammation TNF is involved in clinical problems associated with autoimmune and immune mediated disorders AKA TNF inhibitors Anti TNFs TNF alpha antagonists TNF blockers Specifically refer to engineered macromolecular products Protein based and nucleic acid based drugs which distinguish them from other products like blood components or vaccines Extracted from biological sources Chhina, M. FDA Basics
4 Sugars, proteins or nucleic acids or complex combinations of the these substances May be living entities: Cells and tissues Isolated from a variety of sources: Human, animal or microorganism Produced by biotechnology methods/techniques Gene based & cellular biologics are the forefront of biomedical research Chhina, M. FDA Basics Drugs derived from living cells target specific parts of the immune system & can affect the entire immune system. Used more restrictively for a class of therapeutics that are produced by means of biological processes involving recombinant DNA Personalized medicine revolution The ultimate GMOs 1. Substances that are nearly identical to the body s own signaling proteins Example: Biosynthetic human insulin (Humalin 1982) 4
5 Similar to human immune system to fight off bacteria/viruses Custom designed GMOs made specifically to counteract/block any given substance in the body Examples: Infliximab (Remicade 1998) Adalimumab (Humira 2002) Certolizumab pegol (Cimzia 2008) Based on a naturally occurring receptor linked to the immunoglobulin frame Receptor provides the construct with detailed specificity Example: Etanercept (Enbrel 1998) Aspirin Molecule Monoclonal Antibody Molecule 5
6 Very expensive drug treatments! Costs can vary among insurance companies Depending on which Biologic, out of pocket expenses can add up to hundreds or thousands of dollars Examples: Enbryl: 1 carton (4 injections) can cost an individual $1,500 Remicade: Can cost up to $20,000 per infusion Humira: 1 carton (2 injections) can cost $3,500 6
7 Many biopharmaceutical companies offer patient financial assistance programs Enbryl Financial Assistance Provides up to $8,000/pt /12 month period, including co pays/co insurance and deductible Remicade: RemiStart Rebate Program Eligible commercially insured pt pays $5/infusion for out of pocket costs Humira: AbbieVie Assistance Qualified pts can receive monthly meds potentially free Booming business with R&D of new medicines World s largest drug companies made net profit of $711.4 billion from Companies include: Abbott, Johnson & Johnson, Janssen Biotech, AbbieVie, Amgen, Takeda Brown, T. Medscape 2014 Over the past decade, biologics have accounted for 1/3 of new medicine approvals Currently over 907 medicines and vaccines in development 338 separate mabs in development By 2013, 33 mabs were approved by U.S Report: America s Biopharmaceutical Companies 7
8 It takes approx yrs to bring a new medicine thorough discovery & clinical trials to patients Average cost for R&D is $1.2 billion U.S. accounts for 80% of R&D in health care biotechnology 2013 Report: America s Biopharmaceutical Companies Being chronically ill is EXPENSIVE Big Pharma is making BILLIONS Big Pharma wants patients to use their meds Be your own advocate/patient advocate and research assistance programs. Assess insurance policies May be more of an advantage to have a commercial HMO than a high deductible plan Biologics have made a profound impact in fields of: Rheumatology Dermatology Gastroenterology Neurology 8
9 Biological therapies are designated for patients who have failed or have had inadequate response to conventional medical management of disease processes Typically NOT a first line medication option STEP 1: CXR/TB testing Biologics will compromise immune system and TB can lay dormant for years STEP 3: Complete any antibiotic and be infection free at the start of treatment STEP 2: Live vaccines Should be done 1 3 months before starting treatment Examples of live vaccines: flu mist, shingles, MMR, small pox Symptoms of infusion reactions include flu like illness, fever, chills, nausea and headache Injection site reactions As with any drugs that suppress the immune system, biologic therapy poses some increased to infections and other diseases 9
10 Class: Anti psoriatic, TNF inhibitor FDA approved 1998 Mechanism of action Recombinant human receptor fusion protein Binds and inactivates TNF Prevents synovial inflammation Onset: Between hrs after a single dose Half life: 80 hours, 5 days Pregnancy Category B 10
11 Injection solution Prefilled syringes: 25mg/ml & 50 mg/ml Prefilled auto injector pens: 50 mg/ml Juvenile Rheumatoid Arthritis Adult and Pediatric dosage Not to be given under the age of 2 yrs > 2 yrs < 63 kg: 0.8 mg/kg SC weekly Not to exceed 50 mg weekly > 63 kg: 50 mg SC weekly Adult Rheumatoid Arthritis /Psoriatic Arthritis 50 mg SC q/wk or 25 mg SC 2x/wk given on same day or 3 days apart May be given with or without methotrexate Ankylosing Spondylosis 50 mg SC weekly or 25 mg SC 2x/wk Plaque Psoriasis 50 mg SC 2x/wk x 3 months then 50 mg weekly for maintenance Increased risk for serious infection resulting in hospitalization or death Patients > 65 at greater risk Serious, sometimes fatal infections include reactivation of latent TB & hepatitis B, invasive fungal infections, & bacterial infections Malignancy Lymphoma and other malignancies, some fatal 11
12 Upper respiratory tract infections(38%)*** Injection site reaction (37%) URI (29%) Headache (17%) Rhinitis (12%)*** Nausea (9%) Pharyngitis (7%)*** Heme: Thrombocytopenia, aplastic anemia, leukopenia Hepatobiliary disorders: Autoimmune hepatitis, elevated transaminase Class: Monoclonal antibody FDA approved 1998 Mechanism of action: Recombinant humanized monoclonal anti TNF α Chimeric: 75% Human/25% Mouse mab Prevents synovial and intestinal inflammation Onset: Approximately 2 weeks Half life: 7 40 days* (varies in literature) Pregnancy Category Class B O Brien, K. Microbiology
13 Administration: IV Infusion Adults and Children (6 17 yrs) Dosage RA: 3 mg/kg IV at 0, 2, 6 weeks and q 8 weeks Crohn s/uc /Psoriasis /Plaque Psoriasis: 5 mg/kg IV at 0, 2, 6 weeks and q 8 weeks ***If incomplete response is noted, dose may be increased to 10 mg/kg or increase frequency to every 4 weeks Depends on institution May be premediated with Benadryl, acetaminophen and steroids to avoid infusion reactions IV infusion over 2 4 hrs Monitor patient for acute infusion reactions Do not infuse with any other agents 13
14 Serious infections, sometimes fatal Serious, sometimes fatal blood disorders Lymphoma and solid tissue cancers Liver injury/hepatotoxicity Reactivation of hepatitis B Reactivation of tuberculosis Lethal hepato splenic T cell lymphoma* Drug induced SLE (Lupus like syndrome) Demyelinating CNS disorders Development of antinuclear antibodies (50%) Infection (36%) URI (32%) ***** Nausea (21%) Infusion reaction (20%) Other respiratory infections (12 14%)**** Sinusitis, cough, pharyngitis, bronchitis Rhinitis (8%)***** Lupus like syndrome (<5%) Serious infections and malignancies including melanoma and non melanoma skin cancer 14
15 Class: Monoclonal antibody FDA approved 2002 RA/PA/AS/UC/CD/PP/JIA Mechanism of action: Fully humanized anti TNF α Makes it suitable for long term use Onset: Rapid 2 weeks Half Life: days Pregnancy Class B Administer: SC injection every other wk Auto inject Pen: 40 mg/0.8 ml Prefilled Syringe: 40 mg/0.8 ml; 20 mg/0.4 ml; 10 mg/0.4 ml Adult and Children: > 4 yrs Dosage varies for specific disease processes Induction phase: Day 1: 4 injections Day 15: 2 injections Maintenance: Day 29: 1 injection every other wk 15
16 Serious infections, sometimes fatal Lymphoma and solid tissue cancers Non melanoma skin cancer Hepatic injury Reactivation of tuberculosis Fatal hepato splenic T cell lymphoma* Demyelinating CNS disorders Cardiac failure URI +++ Sinusitis+++ Flu Syndrome Nausea Abdominal Pain Headache Rash Injection Site Reactions 16
17 PRIMARY Lack of improvement of clinical signs during INDUCTION phase WHY? Most cases unexplained Some issues with pt compliance in self admin of drugs Often trial with increased doses/intervals SECONDARY In contrast, pts initially respond to tx and eventually lose response WHY? Complex reasons Pt related factors Immunogenicity Anti drug antibodies Potential hazard of all biologic agents that are engineered molecular targeted therapies Many repeated injections/infusions may trigger antidrug antibodies Antibodies in TNFs are exogenous proteins and are foreign to human immune system Anti drug antibodies decrease efficacy, cause response failure &/or lead to discontinuation of therapy Rosman, Z, Shoenfield, Y, et al: Biologic update:
18 Case Study 47 yo female with hx of UC x 20 yrs Steroid dependent and no longer responding to oral/topical medications Never been able to achieve long term UC remission Disease is progressing to involve entire colon Symptoms are more debilitating with an increase in extra colonic disease manifestations Biologic #1: Remicade 2009: Remicade is started CXR and TB testing completed Induction started and pt was pre medicated with Benadryl, acetaminophen and Decadron Pt reported feeling good after 1 st infusion but slight pain in left thumb after infusion, dismisses symptom #1: Remicade Remicade induction: 0, 2, 6 weeks Pt reports feeling better at week 3 and then had break through symptoms at week 5 Maintenance infusions titrated to q 4 weeks Pt in clinical remission Renewed sense of health & quality of life Forgot what healthy felt like Continues with thumb pain after each infusion but dismisses it as an odd reaction 18
19 7 months on Remicade 2 weeks after infusion reports sudden hives on H&N Symptoms progress Migrating excruciating joint pain/swelling, fever, fatigue, malaise Labwork: Elevated ANA and elevated liver enzymes Dx: Drug induced Lupus & hepatotoxicity Remicade is discontinued Remicade HALF LIFE is ~ days 2011: After 6 months, pt begins Humira Auto injector pens Induction phase Maintenance dose SC q 2 weeks Symptoms better but persistent after 2 months Dose was increased to weekly with good relief Pt resumes active life style, feels healthy again Symptoms better but persistent after 2 months Dose was increased to weekly with good relief 19
20 2 years later, pt experiencing increased symptoms and ultimately acknowledges Humira is no longer keeping symptoms under control. Humira is discontinued due to secondary failure response No adverse effects were noted 11/2012: 51 yo female begins new treatment Induction phase: Self injection auto fill syringes Maintenance dose: 2 syringes q month After several weeks, symptoms improve, pt once again reporting feeling healthy Resumes very active life style and enjoying high quality of life 6/2013: Pt reportedly doing well. Very active, running daily & finishes half marathon. 7/6/2013: Fatigue, malaise, weight loss, low grade temp and sudden onset shortness of breath ER admission for acute SOB Temp F CXR: RLL pneumonia Tx: Levaquin & pain meds 20
21 Back to work in 1 week: just pneumonia Within 10 days, spikes fever F, increased SOB, fatigue PCP Rx: Zithromax CXR unchanged: RLL pneumonia CT scan: Round, dense 6 cm x 4 cm mass in right lower lobe Critical Care/Pulmonology/ID/GI consult Differential Diagnosis: Lymphoma Malignancy Latent TB Opportunistic infection Pulmonary abscess 21
22 Bronchoscopy/Lung biopsy Pt sent home on oral ABX pending biopsy results Bactrim Zithromax Biopsy results No malignancy identified No organism identified to interim ABX tx Biphasic fever & extreme fatigue persists for 12 weeks July 1 September 30, 2013 Persistent symptoms Fever, extreme fatigue, weight loss, productive cough, poor sleep, loss of appetite 10/1/2013: Pt returns to work after 12 weeks Not quite back to baseline, but much improved Takes approx. 6 months to recover from pulmonary infection, but unable to resume active lifestyle Clinically in remission from Cimzia tx 22
23 2015: Severe UC symptoms return 5/2015: Starts ENTYVIO A new anti TNF α approved for IBD in Fall, 2014 Induction: 0, 2, 6 weeks IV infusion over 30 mins Maintenance: q 8 weeks IV Infusion 9/3/15: 1 st maintenance infusion So far, so good Biologic medications are here to stay! Important for all health care providers to be aware of what they are and their potential side effects MUST be aware of ORL adverse effects The FUTURE: Generic forms of biologics are in development and will be marketed as Biosimilars 23
24 This talk is dedicated to my friends and teammates CCFA/Team Challenge: Delaware Valley 24
BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD. crohnsandcolitis.ca
BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD crohnsandcolitis.ca BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD INFLAMMATION AND IMMUNITY IN CROHN S AND COLITIS Inflammation is the body s normal and natural
More informationApproval of a drug under this criteria document does not ensure full coverage of the drug.
Criteria Document: Reference #: PC/B006 Page 1 of 5 and Therapeutics Quality PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS)
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION REMICADE
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REMICADE safely and effectively. See full prescribing information for REMICADE. REMICADE (infliximab)
More informationThe Future Role of Biosimilars: An Unknown Frontier in IBD Treatment
The Future Role of Biosimilars: An Unknown Frontier in IBD Treatment Miguel Regueiro, MD, FACG Professor of Medicine Medical Director, IBD Center Senior Medical Lead, Specialty Homes University of Pittsburgh
More informationA Physician s consideration towards Biosimilars. João Eurico Fonseca
A Physician s consideration towards Biosimilars João Eurico Fonseca Disclosure I received unrestricted research grants or acted as a speaker for Abbvie, Amgen, BMS, Celtrion, Celgene, Janssen, MSD, Novartis,
More informationTreatment: Nutrition and Medication
INFLAMMATORY BOWEL DISEASE (IBD): CROHN S DISEASE Treatment: Nutrition and Medication While there is no cure for Crohn s disease, there are a number of options to help treat it. The goals of treatment
More informationEmerging Medical Therapies in Inflammatory Bowel Disease
Emerging Medical Therapies in Inflammatory Bowel Disease - 2017 Nir Modiano, MD, PhD Assistant Professor of Medicine Division of Gastroenterology & Hepatology Director, Inflammatory Bowel Disease Program
More informationTOP PAPERS FROM 2016: IBD & BIOSIMILARS CYNTHIA SEOW MBBS(HONS), MSC, FRACP UNIVERSITY OF CALGARY CDDW, BANFF, AB MARCH 5, 2017
TOP PAPERS FROM 2016: IBD & BIOSIMILARS CYNTHIA SEOW MBBS(HONS), MSC, FRACP UNIVERSITY OF CALGARY CDDW, BANFF, AB MARCH 5, 2017 FINANCIAL INTEREST DISCLOSURE (OVER THE PAST 24 MONTHS) Speaker: Janssen,
More informationREFERENCE CODE GDHC218CFR PUBLICAT ION DATE FEBRUARY 2014 ULCERATIVE COLITIS - US DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC218CFR PUBLICAT ION DATE FEBRUARY 2014 ULCERATIVE COLITIS - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Sales for Ulcerative Colitis in the United States In 2012,
More informationBiologics in IBD: Optimizing Therapies and Emerging Agents
Optimizing Therapies and Emerging Agents Peter Mannon, MD Professor of Medicine and Microbiology UAB AGS Annual Conference July 1, 2017 Hilton Sandestin Optimizing Therapies and Emerging Agents Optimizing
More informationMEDICATION GUIDE RIBAVIRIN TABLETS Rx Only Read this Medication Guide carefully before you start taking ribavirin tablets and read the Medication
MEDICATION GUIDE RIBAVIRIN TABLETS Rx Only Read this Medication Guide carefully before you start taking ribavirin tablets and read the Medication Guide each time you get more ribavirin tablets. There may
More informationREFERENCE CODE GDHC266CFR PUBLICAT ION DATE DECEMBER 2014 RHEUMATOID ARTHRITIS JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC266CFR PUBLICAT ION DATE DECEMBER 2014 RHEUMATOID ARTHRITIS JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for Rheumatoid Arthritis in Japan The Rheumatoid Arthritis
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm ACG 2017: FDA-EMA workshop on biosimilars Joachim Musaus EMA Product Lead Gastroenterology Human
More informationImmunotherapy in myeloma
Immunotherapy in myeloma This Horizons Infosheet contains information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons Infosheet series provides information relating to
More informationProfessor Ahmed H Al-jedai, PharmD, MBA, BCPS, FCCP, FAST, Saudi Arabia
GaBI Scientific Meetings First GCC Stakeholder Meeting on Approval Process, Interchangeability/Substitution and Safety of Biosimilars 20 November 2017, Holiday Inn Izdihar Riyadh, Saudi Arabia Professor
More informationBiosimilars Scientific Challenges and Implications
Biosimilars Scientific Challenges and Implications Professor Paul Declerck Laboratory for Therapeutic and Diagnostic Antibodies paul.declerck@pharm.kuleuven.be Biological medicinal product A well-defined
More informationINNOVATION ALMOST 180 MILLION EUROS AREAS OF INNOVATION
From health to beauty INNOVATION IMAGINING FUTURE PRODUCTS 40 Investments in R&D reflect the importance that we attach to the discovery and development of innovative therapeutic and well-being solutions,
More informationBL-7040: Oligonucleotide for Inflammatory Bowel Disease
BL-7040: Oligonucleotide for Inflammatory Bowel Disease December 2012 Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects,"
More informationPackage leaflet: Information for the user. Remicade 100 mg powder for concentrate for solution for infusion Infliximab
Package leaflet: Information for the user Remicade 100 mg powder for concentrate for solution for infusion Infliximab Read all of this leaflet carefully before you start using this medicine because it
More informationREFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013 PSORIASIS - Psoriasis - US Drug Forecast and Market Analysis to Executive Summary Sales for Psoriasis in the US 2012 We estimate the 2012 PsO drug
More informationBiogen Idec Synergy Creation in the move to the Big League. Activities, Assets and Sales Figures
Biogen Idec Synergy Creation in the move to the Big League Activities, Assets and Sales Figures Biogen Idec is one of the few integrated firms in the biotechnology industry that manages a drug right from
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationCADTH Canadian Drug Expert Committee Recommendation
CADTH COMMON DRUG REVIEW CADTH Canadian Drug Expert Committee Recommendation (FINAL) Etanercept (Erelzi Sandoz Canada Inc.) Indications: Rheumatoid Arthritis, Ankylosing Spondylitis, Polyarticular Juvenile
More informationUpdate on New MS Therapeutics
Update on New MS Therapeutics William Meador, MD Assistant Professor AAN August 2017 Meeting Disclosures Clinical Trial Involvement: SPRINT-MS Trial MediciNova, ibudilast LemCog Sanofi/Genzyme, alemtuzumab
More informationSafety Data Sheet European Format
Safety Data Sheet European Format 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Preparation Date 26-Jul-2007 Revision Date 09-Sep-2008 Revision Number 3 Product Name Common
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationNational MS Society Information Sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Interferons The interferons are a group of natural proteins that are produced by human cells in response to viral infection
More informationA GUIDE TO THIS REFLECTIONS B RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE
A GUIDE TO THIS REFLECTIONS B327-02 RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE Do you have breast cancer that has spread to outside the breast? Has your tumor tested positive for
More informationContinued Development of Approved Biological Drugs
Continued Development of Approved Biological Drugs A Quantitative Study of Additional Indications Approved Postlaunch in the United States White Paper December 2007 Maya Said Charles-André Brouwers Peter
More informationApplication of Deep Learning to Drug Discovery
Application of Deep Learning to Drug Discovery Hase T, Tsuji S, Shimokawa K, Tanaka H Tohoku Medical Megabank Organization, Tohoku University Current Situation of Drug Discovery Rapid increase of R&D expenditure
More informationBaek, Kyung-min. Recombinant Protein Products Division. Ministry of Food and Drug Safety
Baek, Kyung-min Recombinant Protein Products Division Ministry of Food and Drug Safety About Ministry of Food and Drug Safety Regulation for Biosimilar Principle of Biosimilar Approach Status of Biosimilar
More informationPHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec)
PHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec) INDICATION IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable
More informationREFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013 STELARA (PSORIASIS) - Executive Summary Table below presents key metrics for Stelara in the seven of the nine major pharmaceutical markets. Stelara:
More informationIN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ) ) ) ) ) ) ) ) ) ) ) ) COMPLAINT INTRODUCTION
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ABBVIE INC. and ABBVIE BIOTECHNOLOGY LTD. Plaintiffs, v. AMGEN INC. and AMGEN MANUFACTURING LTD. Defendants. ) ) ) ) ) ) ) ) ) ) ) ) Civil
More informationNaming, tracing, switching and other safety issues after 10 years learning
Naming, tracing, switching and other safety issues after 10 years learning Prof. Dr. Irene Krämer, Department of Pharmacy Johannes Gutenberg-University Medical Center, Mainz (Germany) Disclosures Speaker
More informationPipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016
For more information contact us Pipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016 Copyright. 2016 Advera Health Analytics, Inc. All rights reserved.
More informationNanotechnology: A Brief History and Its Convergence with Medicine. Weston Daniel, PhD Director of Program Management
Nanotechnology: A Brief History and Its Convergence with Medicine Weston Daniel, PhD Director of Program Management Outline Introduction The Nanoscale Applications Realization of a Vision There s Plenty
More informationDrug Development in Inflammatory Bowel Disease: The FDA Perspective
Drug Development in Inflammatory Bowel Disease: The FDA Perspective Kerry Jo Lee, M.D. Division of Gastroenterology and Inborn Errors Products U.S. Food and Drug Administration 1 Disclosure Kerry Jo Lee,
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Transformed Pre- Ig Surface Surface Secreted B- ALL Macroglobulinemia Myeloma
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationApplication of Deep Learning to Drug Discovery
Application of Deep Learning to Drug Discovery Hiroshi Tanaka Tohoku Medical Megabank Orga nization, Tohoku University Current Situation of Drug Discovery Rapid increase of R&D expenditure More than 1B
More informationPatient Case and Question
Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Kenneth H. Shain, MD, PhD Assistant Member H. Lee Moffitt Cancer Center Assistant Professor University of South Florida
More informationThe Science of Monoclonal Antibody Therapy: Introducing Canine Atopic Dermatitis Immunotherapeutic*
The Science of Monoclonal Antibody Therapy: Introducing Canine Atopic Dermatitis Immunotherapeutic* *This product license is conditional. Efficacy and potency test studies are in progress. Michele Rosenbaum,
More informationGuideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
23 July 2015 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular
More informationGuideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
1 2 3 15 November 2012 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous
More informationQuantification of Neutralizing Antibodies to Biopharmaceuticals using a Novel Cell- Bassed Assay Platform Technology
Quantification of Neutralizing Antibodies to Biopharmaceuticals using a Novel Cell- Bassed Assay Platform Technology Michael G Tovey, Director, Laboratory of Viral Oncology, Institut André Lwoff, Villejuif,
More informationAn Overview of Chimeric Antigen Receptor T-cells: CAR-T-ing Away Cancer
An Overview of Chimeric Antigen Receptor T-cells: CAR-T-ing Away Cancer Maxwell Brown, PharmD Clinical Pharmacy Manager, Hematopoietic Stem Cell Transplantation NewYork-Presbyterian/Weill Cornell Medical
More informationEuro Diagnostica ilite Cell-based Reporter Gene Assays
I 1 Euro Diagnostica ilite Cell-based Reporter Gene Assays February 2017 Euro Diagnostica Malmö, Sweden I 3 Euro Diagnostica in brief Founded in 1992 Family owned by Mr Frederik Paulsen (1) Part of Ferring
More informationSandoz Biopharmaceuticals. Sandoz Biosimilars. From concept to reality
Sandoz Biopharmaceuticals Sandoz Biosimilars From concept to reality 2 SANDOZ BIOPHARMACEUTICALS The basics of biosimilars Biosimilars explained Biologic medicines are produced by a complex process involving
More informationPassive vaccination as a global strategy for preventing RSV disease in infants. Filip Dubovsky MD MPH FAAP MedImmune March 2016
Passive vaccination as a global strategy for preventing RSV disease in infants Filip Dubovsky MD MPH FAAP MedImmune March 2016 Outline for Presentation Rationale for passive immunization for RSV prophylaxis
More informationDefining Clinical Benefit in Clinical Trials: FDA Perspective
Defining Clinical Benefit in Clinical Trials: FDA Perspective Jessica J. Lee, MD, MMSc Medical Team Leader Division of Gastroenterology and Inborn Errors Products Center for Drug Evaluation and Research
More informationAMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT
AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Biosimilars Committee on Rheumatologic Care Members of the American College of Rheumatology Medical Societies
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationAssays for Immunogenicity: Are We There Yet?
Assays for Immunogenicity: Are We There Yet? Mark Wener, MD Department of Laboratory Medicine & Rheumatology Division Department of Medicine University of Washington Seattle, WA 98195 wener@uw.edu Goals:
More informationTechnology Overview. 1. Background of Technology. (1) Regulatory Status
Apimeds, Inc. 1 Technology Overview 1. Background of Technology (1) Regulatory Status - New Drug Approval of KFDA (The 6th New Drugs in Korea, The first natural biological drug of its kind). The animal
More informationUse of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals
Use of Antisense ligonucleotides for the Treatment of Inheritable Rare Disorders C. Frank Bennett Isis Pharmaceuticals Agenda Review different antisense strategies Delivery of oligonucleotides to the skin,
More informationand What Can Be Done About It
and What Can Be Done About It John N Galgiani MD www.vfce.arizona.edu is a Western Hemisphere Disease Coccidioidomycosis Spectrum of Disease 100 Infections 60 No Symptoms 40 Symptoms 37 Recover Life-Long
More informationQuo vadis Pharma industry. Vladimír Král, 2015
Quo vadis Pharma industry Vladimír Král, 2015 Steady flow of NCEs and lines extensions in the last years 58 4 15 39 2000 NBE New Combo + New Dosage Form + Vaccines NCE 49 11 14 24 2001 49 5 14 30 2002
More informationSan Francisco Health Service System
San Francisco Health Service System Pharmacy Trends Board Forum: November 10, 2016 Prepared by: Aon s Pharmacy Point of View We Believe Getting patients to the RIGHT drug at the RIGHT channel for the RIGHT
More informationCoordinated Primary Options Service. DVT Management Plan. Management options using Dabigatran or Warfarin
Coordinated Primary Options Service DVT Management Plan Management options using Dabigatran or Warfarin Name NHI DOB Ethnicity Gender Address Contact Information Mobile Home Treatment commenced date *CPO
More informationPLTW Biomedical Science Medical Interventions Course Outline
Follow the fictitious Smith family as you learn about the prevention, diagnosis, and treatment of disease. Play the role of biomedical professionals to analyze case information and diagnose and treat your
More informationPharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.
Pharmacology Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. 1 PHARMACODYNAMIC STUDIES A. Primary pharmacodynamics primary action in target
More informationHeparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Temporal Aspects.
Heparin Induced Eric Kraut, MD Professor of Internal Medicine The Ohio State University Medical Center Heparin Induced Heparin induced thrombocytopenia occurs in up to 5 % of patients receiving unfractionated
More informationInsight to Gene Techno Science Co.,Ltd
Unlimited drug discovery from the beginning Ticker symbol: 4584 Insight to Gene Techno Science Co.,Ltd November 2017 2 Corporate Overview Chief Executive Founded March 2001 Masaharu Tani, President Listed
More informationDeveloping innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO
Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO (lglass@neurenpharma.com) Neuren Pharmaceuticals Created to commercialize University of
More informationSpecialty Drug Spending
Specialty Drug Spending The IMS Institute for Healthcare Informatics reported that spending on specialty pharmaceuticals almost doubled from 2010 to 2015, and spending on this subset of drugs was responsible
More informationTHE BIOLOGIC DRUG MARKET. ebook: The current state of biologic drugs and the challenges ahead
THE BIOLOGIC DRUG MARKET 2 0 1 7 HOW DO DRUGS AND BIOLOGICS DIFFER? This ebook answers that question, and so much more. OptumRx has summarized the complex and expensive world of biologic drugs for you.
More informationClinical Policy: Eculizumab (Soliris) Reference Number: ERX.SPMN.225
Clinical Policy: (Soliris) Reference Number: ERX.SPMN.225 Effective Date: 01/17 Last Review Date: Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationElevated Immunoglobulins and Paraproteins
Elevated Immunoglobulins and Paraproteins NWL Pathology GP Study Afternoon Thursday 19 th October 2017 Dr Aristeidis Chaidos Consultant Haematologist and Honorary Senior Clinical Lecturer Hammersmith Hospital,
More informationGUIDANCE ON THE EVALUATION OF NON ACCREDITED QUALIFICATIONS
GUIDANCE ON THE EVALUATION OF NON ACCREDITED QUALIFICATIONS 1. Introduction 1.1 This document provides guidance notes for the assessment of academic qualifications that have not been formally accredited
More informationEpilogue: Demise of the biosimilar industry and Celltrion s path forward
Epilogue: Demise of the biosimilar industry and Celltrion s path forward The inevitable rise of biosimilars and its equally inexorable demise Having predicted the inevitable rise of biosimilars worldwide,
More informationBiotest AG. Jefferies Healthcare Conference New York, June 7-10, 2016
. Jefferies Healthcare Conference New York, June 7-10, 2016 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial
More informationTreatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Dr Guy Pratt #MyelomaInfodays This talk will cover What is relapse and refractory myeloma Treatment options for relapse Treatment options for refractory
More informationsirna Overview and Technical Tips
1 sirna Overview and Technical Tips 2 CONTENTS 3 4 5 7 8 10 11 13 14 18 19 20 21 Introduction Applications How Does It Work? Handy Tips Troubleshooting Conclusions Further References Contact Us 3 INTRODUCTION
More informationDR NEIL FISHER. Helicon Medical Writing Ltd, Director
PROFILE I am an experienced writer, skilled in writing and editing a wide range of medical communications and healthcare education documents for a variety of audiences. Integral to this is my command of
More informationNOTICE OF SUBSTANTIAL AMENDMENT
NOTICE OF SUBSTANTIAL AMENDMENT For use in the case of all research other than clinical trials of investigational medicinal products (CTIMPs). For substantial amendments to CTIMPs, please use the EU-approved
More informationEbola Facts. October 14, 2014
Ebola Facts October 14, 2014 Symptoms of Ebola Initial symptoms are nonspecific - may include fever, chills, myalgias, and malaise. Patients can progress to develop gastrointestinal symptoms: severe watery
More informationNeutrophil support for patients with cancer receiving myelosuppressive chemotherapy
Appropriate dosing of NEUPOGEN in recovery of neutrophil counts in myelosuppressive regimens Neutrophil support for patients with cancer receiving myelosuppressive chemotherapy Indication NEUPOGEN is indicated
More informationRegulatory Pathways for Rare Diseases
Regulatory Pathways for Rare Diseases Celia M. Witten, Ph.D., M.D. Deputy Director, FDA Center for Biologics Evaluation and Research Emerging Technologies for Rare Diseases: Clinical and Regulatory Case
More informationGMO Technology Conference
GMO Technology Conference The regulation of Clinical Trials on humans involving therapies containing or consisting of genetically modified organisms The Printworks, Dublin Castle 10 th & 11 th October
More informationMassHealth Pharmacy Program: Strategies and Lessons
MassHealth Pharmacy Program: Strategies and Lessons Prepared for Community Catalyst Massachusetts Health Policy Forum November 13, 2009 Cindy Parks Thomas Jeffrey Prottas Schneider Institute for Health
More informationNational Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy
From Hope to Cures: The Value of Biopharmaceutical Innovation National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy HIV/AIDS: Then
More informationAn analysis of the Swedish Biotech Pipeline April, The Swedish Biotechnology Industry Organization
An analysis of the Swedish Biotech Pipeline April, 2007 The Swedish Biotechnology Industry Organization 0 A Survey of the Swedish Biotech pipeline In February-March 2007 a survey of the Swedish biotech
More information2016 OptumRx Trend Insights
2016 OptumRx Trend Insights TREND SUMMARY Overall trend summary This report offers our perspective of the forces driving trend and spending for 2015 vs. 2016. We define trend as growth in year-over-year
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationMyeloma treatment algorithm 1999
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationLecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry
Lecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry Clinical proteomics is the application of proteomic approach to the field of medicine. Proteome of an organism changes
More informationSovaldi Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.25 Subject: Sovaldi Pegasys Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Sovaldi Pegasys
More informationPhase 1 SMA Type 2 Trial Initiation and Study Design. December 2017
Phase 1 SMA Type 2 Trial Initiation and Study Design December 2017 Disclaimers This presentation contains forward-looking statements, including statements about: the timing, progress and results of preclinical
More informationSORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationBiosimilars: An Update on Clinical Trials (Review of Published and Ongoing Studies)
2017;25(1):57-66 REVIEW Biosimilars: An Update on Clinical Trials (Review of Published and Ongoing Studies) Rodica Olteanu, Alexandra Zota, Magda Constantin Colentina Clinical Hospital, Dermatology Department,
More informationPartnering & Networks
Partnering & Networks Success drivers in an ever changing and complex health care system Dr. Benedikt Hoffmann, Senior Manger New Business Development & J&J Innovation Manager October 2 nd, 2014 Judith
More information